Safety and Efficacy of Cryolipolysis Clinical Protocols

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

395 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-04

Study Completion Date

2024-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A single-arm, multicenter interventional clinical study will be conducted. The objective is to evaluate the safety and efficacy of the cryolipolysis technique. Approximately 372 participants will be included. After analyzing the items listed above, the participants in each study will be divided into 3 distinct intervention groups. The individuals included in the study will undergo anamnesis and data collection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cryolipolysis on Localized Adiposity

NCT03160976

Subcutaneous Fat

UNKNOWN NA

Study of White Adipose Tissue Remodeling by Cryolipolysis in Humans

NCT04819321

Lipid Metabolism Disorders Metabolic Disease

UNKNOWN NA

Analyze the Relationship Between the Density of Fat Tissue and Cellulite With the Lumbar Lordosis Degree

NCT02903459

Lordosis

COMPLETED

Effects of Liposuction and Exercise Training on Metabolism, Lipid Profile and Adiposity in Women

NCT01174485

Healthy Subjects

COMPLETED EARLY_PHASE1

Ingestion of Lipids and Changes in Cerebral Blood Flow of People With Obesity

NCT02079116

Obesity

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The participants in each study will be divided into 3 distinct intervention groups (Grupo 1: aplicador 360° M - Região abdominal; Grupo 2: aplicador 360° G - Região abdominal; Grupo 3: aplicador de placas - Região dos flancos). After analyzing the inclusion and exclusion criteria of this study, the individuals included in the study will undergo anamnesis and data collection after the procedure and 6 weeks and 20 weeks after: photographic capture, bioimpedance, perimetry, adipometry and ultrasound imaging of the treated area, in addition to a pain and patient satisfaction questionnaire.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fat Loss

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1 - 360° M applicator, abdominal

Group 1: 360° M applicator - Abdominal region

Group Type EXPERIMENTAL

Polarys Cryolipolysis

Intervention Type DEVICE

The procedure will take place in a session lasting a maximum of 60 minutes, which may vary depending on the amount of fat in the area and the type of applicator chosen (with or without vacuum). The patient will be comfortably positioned, in a position that facilitates suction/fixation of the applicator. An antifreeze membrane will be applied correctly to the skin, avoiding wrinkles. The marked skin area will be positioned in the center of the membrane. The applicator will be positioned in the treatment area at 90° to the skin and will activate the START.

Group 2 - 360° G applicator, abdominal

Group 2: 360° G applicator - Abdominal region

Group Type EXPERIMENTAL

Polarys Cryolipolysis

Intervention Type DEVICE

The procedure will take place in a session lasting a maximum of 60 minutes, which may vary depending on the amount of fat in the area and the type of applicator chosen (with or without vacuum). The patient will be comfortably positioned, in a position that facilitates suction/fixation of the applicator. An antifreeze membrane will be applied correctly to the skin, avoiding wrinkles. The marked skin area will be positioned in the center of the membrane. The applicator will be positioned in the treatment area at 90° to the skin and will activate the START.

Group 3 - flanks

Group 3: Plate applicator - Flank region

Group Type EXPERIMENTAL

Polarys Cryolipolysis

Intervention Type DEVICE

The procedure will take place in a session lasting a maximum of 60 minutes, which may vary depending on the amount of fat in the area and the type of applicator chosen (with or without vacuum). The patient will be comfortably positioned, in a position that facilitates suction/fixation of the applicator. An antifreeze membrane will be applied correctly to the skin, avoiding wrinkles. The marked skin area will be positioned in the center of the membrane. The applicator will be positioned in the treatment area at 90° to the skin and will activate the START.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Polarys Cryolipolysis

The procedure will take place in a session lasting a maximum of 60 minutes, which may vary depending on the amount of fat in the area and the type of applicator chosen (with or without vacuum). The patient will be comfortably positioned, in a position that facilitates suction/fixation of the applicator. An antifreeze membrane will be applied correctly to the skin, avoiding wrinkles. The marked skin area will be positioned in the center of the membrane. The applicator will be positioned in the treatment area at 90° to the skin and will activate the START.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cryolipolysis

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The participant (healthy volunteer) who has read and signed the informed consent form for the study.
* Male or female ≥ 22 years and ≤ 65 years of age.
* Subjects with a body mass index (BMI) of 30 or less and who have a greater volume of adipose tissue in the abdomen (except precordial region) and flanks.
* Subject has not changed in weight more than 5% of body weight in the previous month.
* Subject agrees to maintain his/her weight (i.e., within 5%) by not making major changes in his/her diet or exercise routine during the study.
* Subject agrees to have photographs taken of the treatment area(s) during the scheduled periods.

Exclusion Criteria

* Diabetes mellitus or need to administer or known history of subcutaneous injections in the area of intended treatment (e.g. heparin, insulin) in the last month;
* Metabolic and/or liver diseases that compromise vitamin metabolism;
* Being pregnant or planning to become pregnant during the study period (within the next 8 months);
* Being breast-feeding or having breast-fed in the last 6 months;
* Having a known sensitivity to cold, such as cold urticaria, Raynaud\'s disease, chilblains (pernio) or any known condition with a response to cold exposure that limits blood flow to the skin;
* Irritated skin or presence of dermatitis;
* Keloids or propensity for keloids in the area to be treated;
* Having a history of hernia in the area(s) to be treated.
* Any dermatological conditions, such as moderate to excessive skin laxity, or scarring at the location of the treatment sites that may interfere with treatment or evaluation (stretch marks are not an exclusion);
* Have a history of a bleeding disorder or are taking any medications that, in the opinion of the investigator, may increase the risk of bruising;
* Recent surgery at the treatment site;
* Regular use of anti-inflammatory medications;
* Are taking or have taken any pills or dietary supplements within the past month.
* Invasive fat reduction procedure (e.g., liposuction, mesotherapy) in the intended treatment area;
* Implanted electronic devices (e.g., pacemaker);
* Are currently enrolled in a clinical trial of any unapproved investigational drug or device.
* Any other condition or laboratory value that could, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or pose an unacceptable risk to the subject.

Minimum Eligible Age

22 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes